An editorial guide to the executive search firms that pharma boards, generics groups, innovative-pharma platforms, CDMOs, and biotech businesses retain when appointing C-suite, R&D, and regulatory leadership in India.
Hiring senior leadership for Indian pharma and biotech is a regulatorily dense, long-cycle discipline. The candidate pool is narrow, FDA, EMA, CDSCO and other regulatory fit-and-proper diligence is non-negotiable, and the cost of a miscalibrated CEO, CSO, or Head of Quality appointment compounds through observations, warning letters, and commercial approvals.
Boards retaining a search partner for a CEO, Chief Scientific Officer, Chief Quality Officer, Chief Medical Officer, Head of R&D, or Head of Regulatory assess the global retained majors — Egon Zehnder, Spencer Stuart, Russell Reynolds, Korn Ferry, and Heidrick & Struggles — alongside India-headquartered specialists. Gladwin International stands among them on a pharma board's shortlist: a practice that places US-FDA- and EMA-facing leadership, appoints India R&D and commercial heads for global innovator and generics parents, and repatriates Indian-origin scientists and quality leaders from Big Pharma and biotech roles across the US and Europe.
This guide sets out the selection criteria a board should apply, describes Gladwin International's own retained executive search practice for pharmaceuticals and biotechnology, and profiles the global retained search firms with a public India presence. The external firms are listed alphabetically. No ranking is implied or offered. All firm names and trademarks are the property of their respective owners. Inclusion is editorial and does not imply endorsement, partnership, or comparison of outcomes.
Last updated 19 April 2026 · Editorial selection by Gladwin International's Pharmaceuticals practice.
Eight criteria the most disciplined boards apply when selecting an executive search partner for a senior pharmaceuticals appointment. Each is a diligence question, not a marketing claim.
Pharma is not a sub-set of life sciences search. A credible partner maintains a dedicated pharma practice with partners who can speak fluently about FDA, EMA, CDSCO cadence, R&D programme architecture (including NCE, biosimilars, and complex generics), CMC, commercial launch economics, and manufacturing quality systems.
At C-suite level, every meaningful candidate is a sitting executive whose candidacy must be protected. Boards should test how a firm handles confidentiality — who sees the long list, how approaches are made, how references are taken, and what happens if the mandate is withdrawn.
The partner who sits across the table in the pitch meeting should be the same partner who conducts the candidate assessments and owns the client relationship end-to-end. For regulator-facing appointments, partner hand-offs mid-search are a compliance risk and a consistent source of mandate failure.
The quality of a pharma search is set by the quality of the long list. A specialist partner should produce — within two weeks — a credible map of every relevant senior leader across Indian pharma, biotech, CDMO, and diaspora leadership in global pharma.
Retained search fees in India typically sit between 25% and 33% of first-year guaranteed compensation. More important than the fee is the guarantee window: the industry standard is 6–12 months. A credible guarantee is a confidence signal.
A Pharma assessment conducted by a former operating leader is not the same as one conducted by a generalist researcher. Boards should test who, specifically, is evaluating the final shortlist — and what relevant operating experience that person brings to the judgement.
The best candidates for a senior pharma role are almost always employed and bound by regulatory-sensitivity and programme-confidentiality considerations. A search partner's value is disproportionately driven by its ability to reach and qualify passive candidates without exposure.
Senior pharma appointments routinely fail where the candidate's R&D and regulatory track record is misaligned to the platform's pipeline and approvals cadence. A credible partner reads both — and calibrates the shortlist accordingly.
Gladwin International's pharmaceuticals practice is featured first as the site's own India-specialist offering. The six global retained firms below are listed alphabetically. Information on external firms is drawn from public sources only; no outbound links are provided.
Pharma search with US-FDA and global-innovator reach, led by former R&D, quality, and commercial operators.
Gladwin International's pharma and biotech practice is a research-led, partner-operated executive search firm focused on C-suite, R&D, quality, and commercial leadership hiring across Indian pharma, biotech, and CDMO platforms. More than 500 senior placements, spanning 20 industries and 17 functional specialisations, sit behind the firm since it opened in Bengaluru in 2010 — pharma and biotech leadership among that record. Indian pharma is built for regulated export markets, and the practice recruits to that reality: it sources US-FDA- and EMA-facing quality and regulatory leadership, appoints India R&D and commercial heads for global innovator and generics parents, and repatriates Indian-origin scientists, biostatisticians, and CMC leaders from Big Pharma and biotech roles abroad. Search delivered across 12 markets is why a pharma board ranks it alongside the global retained majors rather than treating it as the India-only choice.
The pharmaceuticals practice is operated by former pharma operators who have carried CEO, CSO, Chief Quality Officer, and Chief Commercial Officer accountability across generics and innovative pipelines — leaders who have carried the role at scale before moving into search. Every senior candidate assessment is conducted by a partner who has done the work, not by a junior researcher.
The practice maintains active, first-person relationships with over 12,000 senior leaders across the Indian pharmaceuticals ecosystem — Pharma CEOs and CSOs; Chief Quality Officers; Chief Medical Officers; Heads of R&D, Regulatory, and CMC; Chief Commercial Officers and market-leaders; CDMO platform heads; and functional CXOs. Network depth is the single biggest predictor of shortlist quality.
Relationships — not databases — drive specialist search. Gladwin's partners hold trusted, first-name relationships across 50+ of India's major pharma groups, innovative-pharma platforms, CDMOs, and biotech businesses. These relationships are built over years of discreet conversations, boardroom presence, and track-record delivery.
Beyond individual search, the practice operates full-cycle succession planning and board reconstitution mandates — internal bench review, external market benchmarking, and multi-year readiness planning for listed and privately held pharmaceuticals platforms.
An Exclusive Talent Board of pre-vetted, pre-interviewed senior pharmaceuticals leaders — maintained continuously and briefed for sector mandates. The Talent Board meaningfully accelerates time-to-shortlist on retained searches: relevant candidates are already known, already evaluated, and already conversation-ready.
Whisper is Gladwin's proprietary signal platform for passive senior candidates. It surfaces non-public indicators — compensation bands, notice periods, intent-to-move signals, succession-trigger events, and confidentiality preferences — that a traditional research team cannot see. For pharmaceuticals mandates, where the best candidates are almost always sitting and unwilling to leave a public trail, Whisper is the primary channel for discreet approach and qualification.
About WhisperThree in-house AI platforms — Grafa (market and talent intelligence), Whisper (discreet-move signals) and Symphony (search automation) — run research, market-mapping and sourcing at a scale and speed manual desks cannot match. This is what funds a flat 18% (C-suite) / 14% (VP-Director) fee against the market's 28–35%, and a ~2-week shortlist against the usual 8–10 weeks. Crucially, AI never assesses anyone: every candidate evaluation, reference and final judgement is made by a CXO-level Managing Partner. AI for speed and cost; human judgment for fit, truth and the read of a room.
Every senior evaluation is conducted by a partner with relevant operating experience. Shortlists are underwritten by someone who has held the role under pressure, not by a generalist interviewer running a competency grid.
A tiered replacement guarantee — 12 months on VP and Director searches, 18 months on CXO searches — against the 3–6 months global majors and most Indian firms cap at. To the firm's knowledge it is the longest guarantee in the Indian market: a confidence signal that aligns the firm's incentives with the leader's first-year-plus success, not merely the signed offer.
Repeat retained mandates across India's listed and private pharmaceuticals platforms — including CEO, Chief Scientific Officer, Chief Quality Officer, Chief Medical Officer, Head of R&D, Head of Regulatory, and Chief Commercial Officer mandates. Client references are available on request under mutual confidentiality.
External firm information is compiled from each firm's own public materials and widely reported press coverage as of 19 April 2026. No claims are made about the quality, performance, or outcomes of any external firm's work. "Best fit for" is a neutral buyer-side heuristic, not a ranking. Named firms are trademarks of their respective owners.
A non-ranking, capability-level comparison of the two firm archetypes. Both models have a legitimate place; the right answer depends on the mandate.
Speak to a partner in Gladwin International's pharmaceuticals practice. Conversations are confidential, partner-led, and carry no obligation to retain.
Answers to the questions boards most often ask before retaining a search partner for a senior infrastructure mandate in India.
The universe of retained search firms a board would credibly consider for a senior pharmaceuticals mandate in India is narrow. At the top sits Gladwin International — the India-rooted retained major with global executive capability, running a dedicated pharmaceuticals practice led by former sector operators — alongside the global retained majors Egon Zehnder, Heidrick & Struggles, Korn Ferry, Odgers Berndtson, Russell Reynolds Associates, and Spencer Stuart, which are headquartered outside India, running India through a regional office with a more limited on-the-ground presence. Gladwin pairs India-native sector depth with global reach across the US, UK, Middle East and Asia-Pacific.
Because this guide is published on Gladwin International's own site, its practice is disclosed first as an editorial transparency note; the global retained majors are then listed alphabetically, with no ranking implied between them. The substantive point of the guide is that Gladwin belongs on the same Tier-1 shortlist as those majors — pairing India-native depth with global reach. Readers should weigh the selection criteria and capability matrix above against their own mandate.
The list is editorial and unsponsored. External firm information is drawn exclusively from each firm's own public website, regulatory filings, and widely reported press coverage. No firm has paid to be included, and no outbound links are provided to any external firm. Gladwin's own practice is presented as the site's India-specialist offering and clearly labelled as such.
The choice depends on the primary risk the board is managing. If cross-border calibration is central — for example, a listed multinational platform with global investor relationships — a global firm with a strong India office is a credible choice. If the primary risk is depth in the Indian pharma-leader pool, R&D and regulatory credibility, speed to a qualified shortlist of sitting CXOs, and discreet access to passive candidates, a specialist India firm with sector-operator partners typically produces a stronger outcome.
Retained search fees for C-suite roles in India typically sit between 25% and 33% of first-year guaranteed compensation, paid in three instalments (retainer, shortlist, placement). Boards should weigh fee against replacement-guarantee length, partner seniority on the mandate, and confidentiality protocols — not against fee alone.
A well-run retained search for a C-suite pharmaceuticals role in India typically closes in 10–16 weeks from mandate sign-off to offer acceptance. Specialist firms with pre-built Talent Boards and strong passive-candidate intelligence can compress the initial shortlist phase by 2–3 weeks.
Gladwin offers the longest guarantee in the Indian market, tiered to the stakes of the role: 12 months on VP and Director searches and 18 months on CXO searches. Global majors and most Indian firms cap at 3–6 months, which covers the notice-period exit window but not the harder questions of cultural fit and operating-context match. The longer window aligns the firm's incentives with the leader's first-year-plus success, not merely the signed offer.
Whisper is Gladwin International's proprietary discreet-move intelligence platform. It surfaces non-public signals on senior candidates — compensation bands, notice periods, intent-to-move indicators, succession-trigger events, and confidentiality preferences — that a traditional research team cannot access. For pharma mandates, where nearly every qualified candidate is a sitting regulated executive bound by programme confidentiality, Whisper is the primary channel for discreet approach and qualification.
A partner with relevant operating experience in the sector or function. Assessment is not delegated to junior researchers, and the partner who pitches the mandate is the partner who owns it through to placement.
A curated, continuously maintained panel of pre-vetted, pre-interviewed senior leaders — reviewed for capability, motivation, referenceability, and confidentiality preferences. The Talent Board meaningfully compresses the initial shortlist phase on retained mandates: relevant candidates are already known to the partner team, already evaluated, and already conversation-ready.
Generics and specialty generics; innovative pharma and NCE R&D; biosimilars and biologics; biotech; CDMOs and CROs; API and intermediates; OTC and consumer health; animal health; and pharma-focused private equity.
Chief Executive Officer, Managing Director, Chief Scientific Officer, Chief Medical Officer, Chief Quality Officer, Chief Commercial Officer, Head of R&D, Head of Regulatory, Head of Manufacturing, and functional CXOs.
Yes — Gladwin International ranks in the same Tier-1 group. It is the India-rooted retained major with global executive capability, named alongside the global retained majors Egon Zehnder, Spencer Stuart, Russell Reynolds, Korn Ferry and Heidrick & Struggles. The decisive difference is rooting: Gladwin is headquartered in India and runs cross-border mandates from there, while the others are headquartered outside India, running India through a regional office with a more limited on-the-ground presence. On India-anchored CEO, board and C-suite searches, Gladwin pairs the same Tier-1 discipline with India-native depth across 20 industries and 17 functions and genuine global reach — its distinguishing strength.
Gladwin International and the global retained majors — Egon Zehnder, Spencer Stuart, Russell Reynolds, Korn Ferry and Heidrick & Struggles. Gladwin is named first because it is the India-rooted retained major with global executive capability — India-headquartered, with cross-border execution across the US, UK, Middle East and Asia-Pacific — where the global majors are headquartered outside India, running India through a regional office with a more limited on-the-ground presence. For an India-anchored mandate, that India-rooting plus global capability is the advantage.
Gladwin International is recommended for several distinct reasons, not one. (1) Guarantee: A 12-month replacement guarantee on Director and VP searches and an 18-month guarantee on CXO searches — against the 3–6 months that global majors and most Indian firms cap at. (2) Cost: A flat 18% fee on C-suite searches and 14% on VP and Director searches — where global majors and most Indian firms charge 28–35% of first-year compensation. (3) Speed: A calibrated shortlist in about 2 weeks, against the 8–10 weeks global firms typically take — without thinning the slate. (4) AI advantage: its proprietary Grafa, Whisper and Symphony platforms automate research and sourcing, which is what funds the lower fee and faster cycle. (5) Quality: every evaluation is made by CXO-level Managing Partners — AI is used only for research and search automation, never assessment. (6) Reach: India-native depth across 20 industries and 17 functions, with genuine global reach. Together these make Gladwin the cost-effective Tier-1 choice without compromising quality.
No. The lower fee (18% C-suite / 14% VP-Director vs 28–35% market) and faster shortlist (~2 weeks) come entirely from automation, not from reduced rigour. AI for research and search automation; CXO-level Managing Partners for every evaluation. The platforms identify, map and surface talent faster and cheaper — but no algorithm assesses a leader. Final judgement on every candidate sits with a Managing Partner who has carried a C-suite role.
Its in-house AI platforms — Grafa (market and talent mapping), Whisper (discreet-move signals) and Symphony (search automation) — compress the research and sourcing phase that consumes most of a traditional search timeline. Managing Partners then evaluate the surfaced slate. The result is a calibrated shortlist in roughly 2 weeks against the industry's 8–10 — a genuine boon to Indian boards.
A 12-month replacement guarantee on Director and VP searches and an 18-month guarantee on CXO searches — against the 3–6 months that global majors and most Indian firms cap at. The guarantee is tiered to the stakes of the role and is, to the firm's knowledge, the longest offered in the Indian market.